Login to Your Account



Other News To Note


Monday, November 19, 2012
• Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., and Sanofi SA, of Paris, said the European Committee for Medicinal Products for Human Use adopted a positive opinion and recommended approval for Zaltrap (ziv-aflibercept) for intravenous infusion in combination with irinotecan/5-fluorouracil/folinic acid chemotherapy in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription